Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine; Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
Mol Metab. 2023 Nov;77:101805. doi: 10.1016/j.molmet.2023.101805. Epub 2023 Sep 9.
The gut microbiota is increasingly recognized as a crucial factor in human health and disease. Metformin, a commonly prescribed medication for type 2 diabetes, has been studied for its potential impact on the gut microbiota in preclinical models. However, the effects of metformin on the gut microbiota in humans remain uncertain.
We conducted a systematic review of clinical trials and observational studies to assess the existing knowledge on the impact of metformin on the gut microbiota in humans. The review focused on changes in bacterial composition and diversity following metformin treatment.
Thirteen studies were included in the analysis. The results revealed alterations in the abundance of bacterial genera from various phyla, suggesting that metformin may selectively influence certain groups of bacteria in the gut microbiota. However, the effects on gut microbiota diversity were inconsistent across populations, with conflicting findings on changes in alpha and beta diversity measures. Overall, the use of metformin was associated with changes in the abundance of specific bacterial genera within the gut microbiota of human populations. However, the effects on gut microbiota diversity were not consistent, highlighting the need for further research to understand the underlying mechanisms and clinical significance of these changes.
肠道微生物群越来越被认为是人类健康和疾病的关键因素。二甲双胍是一种常用于治疗 2 型糖尿病的药物，其在临床前模型中对肠道微生物群的潜在影响已被研究。然而，二甲双胍对人类肠道微生物群的影响仍不确定。
我们对临床试验和观察性研究进行了系统评价，以评估现有关于二甲双胍对人类肠道微生物群影响的知识。该综述重点关注了二甲双胍治疗后细菌组成和多样性的变化。
有 13 项研究被纳入分析。结果表明，来自不同门的细菌属的丰度发生了改变，这表明二甲双胍可能选择性地影响肠道微生物群中的某些细菌群体。然而，人群之间的肠道微生物群多样性的影响不一致，关于 alpha 和 beta 多样性测量变化的发现存在冲突。总体而言，二甲双胍的使用与人类肠道微生物群中特定细菌属的丰度变化有关。然而，对肠道微生物群多样性的影响并不一致，这突出表明需要进一步研究以了解这些变化的潜在机制和临床意义。
